Related Experiment Videos
Frequency of CYP2D6 allelic variants in multiple sclerosis
J A Agúndez1, R Arroyo, M C Ledesma
1Department of Pharmacology, University of Extremadura (Badajoz), University Hospitals, Madrid, Spain.
Abstract:
Recent reports have shown association between CYP2D6 polymorphism and neuronal degenerative diseases such as Parkinson's disease. We investigated the association between this polymorphism and the risk for developing multiple sclerosis (MS). Leucocyte DNA from 118 MS patients and a control group of 200 unrelated healthy individuals was studied for the occurrence of 8 different CYP2D6 allelic variants by using allele-specific PCR amplification, XbaI and EcoRI RFLP analyses. The frequencies for these allelic variants in the MS and control groups were, respectively: CYP2D6wt 75.0% and 79.3%, CYP2D6A 0.4% and 1.3%, CYP2D6B 11.4% and 12.0%, CYP2D6C 4.2% and 2.0%, CYP2D6D 3.0% and 2.3%, CYP2D6L 0.8% and 0.3%, CYP2D6L2 5.1% and 3.0%. The frequencies of subjects with high CYP2D6 activity (those carrying two or more functional genes) were 77.1% and 73.5% in MS and control groups. The frequencies of subjects with absent CYP2D6 activity (those lacking functional genes) were 3.4% and 4.5% in MS and control groups, respectively. These results indicate that mutations at the CYP2D6 gene do not seem to be a factor in determining susceptibility to MS.
Insights
CYP2D6 gene variations are not associated with an increased risk of developing multiple sclerosis (MS). This study found no significant differences in CYP2D6 allelic variants between MS patients and healthy individuals, suggesting it is not a susceptibility factor for MS.
Area of Science:
- Genetics
- Neuroimmunology
- Pharmacogenomics
Background:
- Polymorphisms in the CYP2D6 gene are linked to neurodegenerative diseases like Parkinson's.
- Understanding genetic factors in multiple sclerosis (MS) susceptibility is crucial for disease management.
Purpose of the Study:
- To investigate the potential association between CYP2D6 gene polymorphism and the risk of developing multiple sclerosis (MS).
Main Methods:
- Genotyping of 8 different CYP2D6 allelic variants in 118 MS patients and 200 healthy controls.
- Utilized allele-specific PCR amplification and RFLP analyses (XbaI, EcoRI) for variant detection.
Main Results:
- No significant differences in the frequencies of specific CYP2D6 allelic variants were observed between MS patients and the control group.
- Frequencies of individuals with high or absent CYP2D6 activity did not differ significantly between the MS and control cohorts.
Conclusions:
- CYP2D6 gene mutations do not appear to be a significant factor in determining susceptibility to multiple sclerosis.
- Further research may explore other genetic markers for MS risk.